An in vivo screening system to identify tumorigenic genes

T. Ihara, Y. Hosokawa, K. Kumazawa, K. Ishikawa, J. Fujimoto, M. Yamamoto, T. Muramkami, N. Goshima, E. Ito, S. Watanabe, Kentaro Senba

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    Screening for oncogenes has mostly been performed by in vitro transformation assays. However, some oncogenes might not exhibit their transforming activities in vitro unless putative essential factors from in vivo microenvironments are adequately supplied. Here, we have developed an in vivo screening system that evaluates the tumorigenicity of target genes. This system uses a retroviral high-efficiency gene transfer technique, a large collection of human cDNA clones corresponding to ~70% of human genes and a luciferase-expressing immortalized mouse mammary epithelial cell line (NMuMG-luc). From 845 genes that were highly expressed in human breast cancer cell lines, we focused on 205 genes encoding membrane proteins and/or kinases as that had the greater possibility of being oncogenes or drug targets. The 205 genes were divided into five subgroups, each containing 34–43 genes, and then introduced them into NMuMG-luc cells. These cells were subcutaneously injected into nude mice and monitored for tumor development by in vivo imaging. Tumors were observed in three subgroups. Using DNA microarray analyses and individual tumorigenic assays, we found that three genes, ADORA2B, PRKACB and LPAR3, were tumorigenic. ADORA2B and LPAR3 encode G-protein-coupled receptors and PRKACB encodes a protein kinase A catalytic subunit. Cells overexpressing ADORA2B, LPAR3 or PRKACB did not show transforming phenotypes in vitro, suggesting that transformation by these genes requires in vivo microenvironments. In addition, several clinical data sets, including one for breast cancer, showed that the expression of these genes correlated with lower overall survival rate.Oncogene advance online publication, 3 October 2016; doi:10.1038/onc.2016.351.

    Original languageEnglish
    JournalOncogene
    DOIs
    Publication statusAccepted/In press - 2016 Oct 3

    Fingerprint

    Oncogenes
    Genes
    Breast Neoplasms
    Cell Line
    Gene Transfer Techniques
    Microarray Analysis
    G-Protein-Coupled Receptors
    Cyclic AMP-Dependent Protein Kinases
    Oligonucleotide Array Sequence Analysis
    Luciferases
    Nude Mice
    Protein Kinases
    Publications
    Catalytic Domain
    Neoplasms
    Membrane Proteins
    Breast
    Complementary DNA
    Clone Cells
    Epithelial Cells

    ASJC Scopus subject areas

    • Molecular Biology
    • Genetics
    • Cancer Research

    Cite this

    Ihara, T., Hosokawa, Y., Kumazawa, K., Ishikawa, K., Fujimoto, J., Yamamoto, M., ... Senba, K. (Accepted/In press). An in vivo screening system to identify tumorigenic genes. Oncogene. https://doi.org/10.1038/onc.2016.351

    An in vivo screening system to identify tumorigenic genes. / Ihara, T.; Hosokawa, Y.; Kumazawa, K.; Ishikawa, K.; Fujimoto, J.; Yamamoto, M.; Muramkami, T.; Goshima, N.; Ito, E.; Watanabe, S.; Senba, Kentaro.

    In: Oncogene, 03.10.2016.

    Research output: Contribution to journalArticle

    Ihara, T, Hosokawa, Y, Kumazawa, K, Ishikawa, K, Fujimoto, J, Yamamoto, M, Muramkami, T, Goshima, N, Ito, E, Watanabe, S & Senba, K 2016, 'An in vivo screening system to identify tumorigenic genes', Oncogene. https://doi.org/10.1038/onc.2016.351
    Ihara T, Hosokawa Y, Kumazawa K, Ishikawa K, Fujimoto J, Yamamoto M et al. An in vivo screening system to identify tumorigenic genes. Oncogene. 2016 Oct 3. https://doi.org/10.1038/onc.2016.351
    Ihara, T. ; Hosokawa, Y. ; Kumazawa, K. ; Ishikawa, K. ; Fujimoto, J. ; Yamamoto, M. ; Muramkami, T. ; Goshima, N. ; Ito, E. ; Watanabe, S. ; Senba, Kentaro. / An in vivo screening system to identify tumorigenic genes. In: Oncogene. 2016.
    @article{db3fabccb6314230899cf0458024721f,
    title = "An in vivo screening system to identify tumorigenic genes",
    abstract = "Screening for oncogenes has mostly been performed by in vitro transformation assays. However, some oncogenes might not exhibit their transforming activities in vitro unless putative essential factors from in vivo microenvironments are adequately supplied. Here, we have developed an in vivo screening system that evaluates the tumorigenicity of target genes. This system uses a retroviral high-efficiency gene transfer technique, a large collection of human cDNA clones corresponding to ~70{\%} of human genes and a luciferase-expressing immortalized mouse mammary epithelial cell line (NMuMG-luc). From 845 genes that were highly expressed in human breast cancer cell lines, we focused on 205 genes encoding membrane proteins and/or kinases as that had the greater possibility of being oncogenes or drug targets. The 205 genes were divided into five subgroups, each containing 34–43 genes, and then introduced them into NMuMG-luc cells. These cells were subcutaneously injected into nude mice and monitored for tumor development by in vivo imaging. Tumors were observed in three subgroups. Using DNA microarray analyses and individual tumorigenic assays, we found that three genes, ADORA2B, PRKACB and LPAR3, were tumorigenic. ADORA2B and LPAR3 encode G-protein-coupled receptors and PRKACB encodes a protein kinase A catalytic subunit. Cells overexpressing ADORA2B, LPAR3 or PRKACB did not show transforming phenotypes in vitro, suggesting that transformation by these genes requires in vivo microenvironments. In addition, several clinical data sets, including one for breast cancer, showed that the expression of these genes correlated with lower overall survival rate.Oncogene advance online publication, 3 October 2016; doi:10.1038/onc.2016.351.",
    author = "T. Ihara and Y. Hosokawa and K. Kumazawa and K. Ishikawa and J. Fujimoto and M. Yamamoto and T. Muramkami and N. Goshima and E. Ito and S. Watanabe and Kentaro Senba",
    year = "2016",
    month = "10",
    day = "3",
    doi = "10.1038/onc.2016.351",
    language = "English",
    journal = "Oncogene",
    issn = "0950-9232",
    publisher = "Nature Publishing Group",

    }

    TY - JOUR

    T1 - An in vivo screening system to identify tumorigenic genes

    AU - Ihara, T.

    AU - Hosokawa, Y.

    AU - Kumazawa, K.

    AU - Ishikawa, K.

    AU - Fujimoto, J.

    AU - Yamamoto, M.

    AU - Muramkami, T.

    AU - Goshima, N.

    AU - Ito, E.

    AU - Watanabe, S.

    AU - Senba, Kentaro

    PY - 2016/10/3

    Y1 - 2016/10/3

    N2 - Screening for oncogenes has mostly been performed by in vitro transformation assays. However, some oncogenes might not exhibit their transforming activities in vitro unless putative essential factors from in vivo microenvironments are adequately supplied. Here, we have developed an in vivo screening system that evaluates the tumorigenicity of target genes. This system uses a retroviral high-efficiency gene transfer technique, a large collection of human cDNA clones corresponding to ~70% of human genes and a luciferase-expressing immortalized mouse mammary epithelial cell line (NMuMG-luc). From 845 genes that were highly expressed in human breast cancer cell lines, we focused on 205 genes encoding membrane proteins and/or kinases as that had the greater possibility of being oncogenes or drug targets. The 205 genes were divided into five subgroups, each containing 34–43 genes, and then introduced them into NMuMG-luc cells. These cells were subcutaneously injected into nude mice and monitored for tumor development by in vivo imaging. Tumors were observed in three subgroups. Using DNA microarray analyses and individual tumorigenic assays, we found that three genes, ADORA2B, PRKACB and LPAR3, were tumorigenic. ADORA2B and LPAR3 encode G-protein-coupled receptors and PRKACB encodes a protein kinase A catalytic subunit. Cells overexpressing ADORA2B, LPAR3 or PRKACB did not show transforming phenotypes in vitro, suggesting that transformation by these genes requires in vivo microenvironments. In addition, several clinical data sets, including one for breast cancer, showed that the expression of these genes correlated with lower overall survival rate.Oncogene advance online publication, 3 October 2016; doi:10.1038/onc.2016.351.

    AB - Screening for oncogenes has mostly been performed by in vitro transformation assays. However, some oncogenes might not exhibit their transforming activities in vitro unless putative essential factors from in vivo microenvironments are adequately supplied. Here, we have developed an in vivo screening system that evaluates the tumorigenicity of target genes. This system uses a retroviral high-efficiency gene transfer technique, a large collection of human cDNA clones corresponding to ~70% of human genes and a luciferase-expressing immortalized mouse mammary epithelial cell line (NMuMG-luc). From 845 genes that were highly expressed in human breast cancer cell lines, we focused on 205 genes encoding membrane proteins and/or kinases as that had the greater possibility of being oncogenes or drug targets. The 205 genes were divided into five subgroups, each containing 34–43 genes, and then introduced them into NMuMG-luc cells. These cells were subcutaneously injected into nude mice and monitored for tumor development by in vivo imaging. Tumors were observed in three subgroups. Using DNA microarray analyses and individual tumorigenic assays, we found that three genes, ADORA2B, PRKACB and LPAR3, were tumorigenic. ADORA2B and LPAR3 encode G-protein-coupled receptors and PRKACB encodes a protein kinase A catalytic subunit. Cells overexpressing ADORA2B, LPAR3 or PRKACB did not show transforming phenotypes in vitro, suggesting that transformation by these genes requires in vivo microenvironments. In addition, several clinical data sets, including one for breast cancer, showed that the expression of these genes correlated with lower overall survival rate.Oncogene advance online publication, 3 October 2016; doi:10.1038/onc.2016.351.

    UR - http://www.scopus.com/inward/record.url?scp=84989917537&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84989917537&partnerID=8YFLogxK

    U2 - 10.1038/onc.2016.351

    DO - 10.1038/onc.2016.351

    M3 - Article

    JO - Oncogene

    JF - Oncogene

    SN - 0950-9232

    ER -